ES2532527T3 - Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis - Google Patents

Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis Download PDF

Info

Publication number
ES2532527T3
ES2532527T3 ES10779906.6T ES10779906T ES2532527T3 ES 2532527 T3 ES2532527 T3 ES 2532527T3 ES 10779906 T ES10779906 T ES 10779906T ES 2532527 T3 ES2532527 T3 ES 2532527T3
Authority
ES
Spain
Prior art keywords
psoriasis
adrenergic receptor
prevention
treatment
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10779906.6T
Other languages
English (en)
Spanish (es)
Inventor
Jack A. Dejovin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Laboratories LP
Original Assignee
Galderma Laboratories LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Laboratories LP filed Critical Galderma Laboratories LP
Application granted granted Critical
Publication of ES2532527T3 publication Critical patent/ES2532527T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES10779906.6T 2009-11-19 2010-11-18 Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis Active ES2532527T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US621942 2009-11-19
US12/621,942 US8394800B2 (en) 2009-11-19 2009-11-19 Method for treating psoriasis
PCT/US2010/057184 WO2011075267A1 (en) 2009-11-19 2010-11-18 Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis

Publications (1)

Publication Number Publication Date
ES2532527T3 true ES2532527T3 (es) 2015-03-27

Family

ID=43729952

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10779906.6T Active ES2532527T3 (es) 2009-11-19 2010-11-18 Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis

Country Status (13)

Country Link
US (2) US8394800B2 (enExample)
EP (1) EP2501373B1 (enExample)
JP (1) JP5680660B2 (enExample)
KR (2) KR101374907B1 (enExample)
CN (1) CN102844025B (enExample)
AU (1) AU2010332233C1 (enExample)
BR (1) BR112012012131A2 (enExample)
CA (1) CA2781112C (enExample)
ES (1) ES2532527T3 (enExample)
MX (1) MX2012005790A (enExample)
NZ (1) NZ600333A (enExample)
RU (1) RU2538729C2 (enExample)
WO (1) WO2011075267A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
RU2535008C2 (ru) 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
SG189896A1 (en) 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
WO2016052947A1 (ko) * 2014-09-29 2016-04-07 (주)네오팜 건성 치료용 산성 외용제 조성물
US20220211672A1 (en) * 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
FR2648709A1 (fr) 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ES2187533T3 (es) * 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
US6117871A (en) * 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
JP2001512471A (ja) 1997-02-21 2001-08-21 バイヤースドルフ・アクチエンゲゼルシヤフト しゅさの処置のための調製物
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
ES2220257T1 (es) * 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
AU5331200A (en) 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
US6147102A (en) * 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) * 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040092482A1 (en) * 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) * 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
WO2004103233A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
BRPI0414277A (pt) * 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
US7239705B2 (en) 2003-12-10 2007-07-03 Motorola Inc. Apparatus and method for broadcast services transmission and reception
WO2005070465A2 (en) 2004-01-14 2005-08-04 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CA2567401C (en) * 2004-05-25 2013-11-12 Sansrosa Pharmaceutical Development, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US8158161B2 (en) * 2005-01-12 2012-04-17 S.U.L.V.E. Ltd. Methods and pharmaceutical compositions useful for treating psoriasis
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
PT2252290T (pt) * 2008-02-15 2018-02-14 Bone Therapeutics Sa Composição farmacêutica para utilização no tratamento e/ou prevenção de doenças osteoarticulares
EP2090307A1 (en) 2008-02-15 2009-08-19 Bone Therapeutics Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
JP5728234B2 (ja) * 2008-02-15 2015-06-03 ボーン・セラピューティクス 骨関節疾患の治療又は予防において使用するための医薬組成物
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Also Published As

Publication number Publication date
CN102844025B (zh) 2014-11-19
CN102844025A (zh) 2012-12-26
WO2011075267A1 (en) 2011-06-23
JP5680660B2 (ja) 2015-03-04
BR112012012131A2 (pt) 2019-09-24
CA2781112A1 (en) 2011-06-23
EP2501373A1 (en) 2012-09-26
AU2010332233A1 (en) 2012-06-14
US20130184283A1 (en) 2013-07-18
KR101374907B1 (ko) 2014-03-14
RU2012125249A (ru) 2013-12-27
JP2013511534A (ja) 2013-04-04
RU2538729C2 (ru) 2015-01-10
EP2501373B1 (en) 2015-02-25
CA2781112C (en) 2015-01-06
HK1175698A1 (en) 2013-07-12
US9072739B2 (en) 2015-07-07
KR20130106439A (ko) 2013-09-27
MX2012005790A (es) 2012-09-28
US8394800B2 (en) 2013-03-12
NZ600333A (en) 2014-05-30
KR20120129878A (ko) 2012-11-28
US20110118267A1 (en) 2011-05-19
AU2010332233C1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
ES2532527T3 (es) Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis
PA8850801A1 (es) Compuestos útiles para inhibir chk1
CL2009000533A1 (es) Uso de una variante de defensina parenteral contra la tuberculosis; que comprende una sustitucion d9s en el polipeptido maduro; metodo para eliminar o inhibir mycobacterium in vitro.
UY32045A (es) Compuesto amida
HN2010002030A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CL2011001464A1 (es) Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico.
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
ES2666397T3 (es) Activación de CD89 en terapia
MX2013003076A (es) Terapeuticos contra cancer de mama.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
MX2011011656A (es) Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento.
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
WO2011061252A3 (en) Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder
PA8784901A1 (es) Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.